Denosumab for treatment of hypercalcemia of malignancy. - Wikidata - wikimedia - TriplyDB

Denosumab for treatment of hypercalcemia of malignancy.

Denosumab for treatment of hypercalcemia of malignancy.

http://www.wikidata.org/entity/Q34130902

about

Hypercalcemia of Malignancy: An Update on Pathogenesis and Management Hypercalcemia of malignancy and new treatment options Hypercalcemia of Malignancy A review in the treatment of oncologic emergencies.Prevalence of hypercalcemia of malignancy among pediatric cancer patients in the UK Clinical Practice Research Datalink database.Denosumab: a new agent in the management of hypercalcemia of malignancy.AACR Cancer Progress Report 2015 Hypercalcaemia and hypocalcaemia: finding the balance.Denosumab: an Emerging Therapy in Pediatric Bone Disorders.Hypercalcemia of Malignancy and Colorectal Cancer.Skeletal complications in cancer patients with bone metastases.Nephrotoxicity of anticancer treatment.Clinical Assessment and Management of Delirium in the Palliative Care Setting Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies.Denosumab Therapy for Refractory Hypercalcemia Secondary to Squamous Cell Carcinoma of Skin in Epidermolysis Bullosa.Malignancy-Related Hypercalcemia in Advanced Solid Tumors: Survival Outcomes.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.[Metabolic disorders as paraneoplastic syndromes].Follicular lymphoma presenting with hypercalcaemia: an unusual mechanism of hypercalcaemia.

P2860

Q26771719-5A4322D2-7578-41EC-942C-773D5C6D3EAC Q26775300-D0BDC837-F5C5-4DD6-B310-664CE2A2C24D Q28079418-13AC2751-9810-4B20-B6E9-E12672720D02 Q30252082-E97E7B88-3C51-43DC-9F57-A8F6A9FC38FD Q33821138-0C906451-2B09-445F-9366-5CB721C45D9B Q37158465-62F49909-2251-4458-8440-724B15A0C584 Q37210896-C74C9F93-054A-471D-AE0E-5366E8FA19A6 Q37736066-460AB0B8-7590-4E1C-AD83-050C4D271D4B Q38712724-F24D2A15-AD50-4FB6-A894-C607F53FE974 Q38782895-CFDEEA08-7BE2-4310-9D08-F1A6C93FB42F Q38917438-802A0619-4D1F-4D5B-8D82-3AC33D51B14E Q39198933-CBCF29EC-89BA-4FE8-BC2C-6FFF0DC305C8 Q42182792-A336CC6D-52AE-4EB4-AE29-08D89A8A2BF9 Q42327962-B6620483-BDC7-4E7C-9520-D197F4462BB1 Q43973225-73A82FCB-4E3D-4B82-AC0A-A45F224387CA Q47095666-A499F126-C06F-4583-8058-6C46FA8612BC Q49539698-52F2D7C4-9555-4151-9610-C080974752F8 Q49581415-1EA9FB5B-9D10-48C3-A849-1242954A3F48 Q53676645-EA5D0438-B98F-4319-90A6-CD01491BA37E

P2860

Denosumab for treatment of hypercalcemia of malignancy.

http://www.wikidata.org/entity/Q34130902

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Denosumab for treatment of hypercalcemia of malignancy.

@ast

Denosumab for treatment of hypercalcemia of malignancy.

@en

Denosumab for treatment of hypercalcemia of malignancy.

@nl

type

label

Denosumab for treatment of hypercalcemia of malignancy.

@ast

Denosumab for treatment of hypercalcemia of malignancy.

@en

Denosumab for treatment of hypercalcemia of malignancy.

@nl

prefLabel

Denosumab for treatment of hypercalcemia of malignancy.

@ast

Denosumab for treatment of hypercalcemia of malignancy.

@en

Denosumab for treatment of hypercalcemia of malignancy.

@nl

P1433

Q34130902-00B5BB82-E0E4-48D0-A9FA-B20B70B00A35

P1476

Q34130902-D20BCDAD-22B3-4597-9E0E-4AE426BF30BF

P2093

Q34130902-298B2A9A-E5EE-4E54-88B4-F92CB5308ADF

Q34130902-48879BD6-0617-4FD6-8B78-AB35BCC6F74F

Q34130902-530F0BF7-7A5C-4D14-9582-6FFCBB4A1B5C

Q34130902-57562076-6613-4422-9BD8-08F7728AA314

Q34130902-7B653EDE-E7DC-420A-98B3-0E7351E6E75F

Q34130902-8ED32855-8126-44DE-9F0D-277FD25348B7

Q34130902-9E502223-03B5-401E-890B-D2CFEA5B2BD8

Q34130902-9FA955A7-17F5-4975-9F55-18E72E2CE062

Q34130902-A9641A9B-2FCF-4262-ACEB-002CE8A836C6

Q34130902-C48BBD2E-F285-43D2-B928-17FA70B95CA2

P2860

Q34130902-0504C6F1-34B8-45A6-B03C-1E2BEF6DCC31

Q34130902-0D932DFE-E53D-45CC-ABBF-C6F6716FF242

Q34130902-0DD5F725-291C-4DD0-882F-F6D7AE509E6A

Q34130902-0E67FDE0-8D30-4E13-9CF4-BB10C52470D1

Q34130902-12A37033-97B4-4AE9-94F4-A17025B3F32F

Q34130902-2FE62670-677F-44A0-B2FB-9685688FFD0C

Q34130902-53F6BE11-EECA-472C-A17F-5465B714FA20

Q34130902-5F38A163-7EE6-407C-B156-75DE9FC8051D

Q34130902-686C6A49-F1CC-4C90-A8F4-A3A7928C7B26

Q34130902-6D3F9FA3-F7B5-4785-8EF0-31B708949BCB

P304

Q34130902-9F37D703-5C16-475B-BDB3-0FB07AC1ED8C

P31

Q34130902-DEA4889F-38FD-4298-BBFD-A1A5773107E7

P356

Q34130902-898F4CE6-687B-4E94-B17C-949CD4DAE143

P407

Q34130902-9854BDC6-EAF8-45B7-ABAA-F2BF1DB8D470

P433

Q34130902-1BE182E6-85A6-44C5-AA73-33F3E16FB26C

P478

Q34130902-4956E07D-FFBC-4F1D-8D85-EF0A34EDB562

P50

Q34130902-52D063E5-6BA5-4992-B1C7-3BBFD2B49318

Q34130902-BAAE35FE-414A-410E-86E6-C27B1F3FD19D

Q34130902-E074BEAA-0454-4886-8C89-8B9EF41FAB11

P577

Q34130902-193F79A9-DD9B-440A-8CF1-F649F2EC7353

P5875

Q34130902-4222E45C-09D0-4252-AE99-ACC5F6C461FF

P698

Q34130902-AA8F645C-BD37-4A20-B45A-C6BC3BE54D6F

P932

Q34130902-8F0172E1-F2C2-46D3-B553-F184122E9C44

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Denosumab for treatment of hypercalcemia of malignancy

@en

P2093

Ada Braun

http://www.w3.org/2001/XMLSchema#string

Alberto Bessudo

http://www.w3.org/2001/XMLSchema#string

Bennett Yu

http://www.w3.org/2001/XMLSchema#string

Diego Tosi

http://www.w3.org/2001/XMLSchema#string

Giuseppe Tonini

http://www.w3.org/2001/XMLSchema#string

Mimi I Hu

http://www.w3.org/2001/XMLSchema#string

Paul Zorsky

http://www.w3.org/2001/XMLSchema#string

Rajul K Jain

http://www.w3.org/2001/XMLSchema#string

Rasim Gucalp

http://www.w3.org/2001/XMLSchema#string

Sophie Leboulleux

http://www.w3.org/2001/XMLSchema#string

P2860

Parathyroid hormone-related protein purified from a human lung cancer cell line

Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia.

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.

Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.

Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone.

Clinical practice. Hypercalcemia associated with cancer.

Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.

Narrative review: furosemide for hypercalcemia: an unproven yet common practice.

Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients.

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.

P304

3144-3152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2014-1001

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

Ilya G Glezerman

P577

2014-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262977271

http://www.w3.org/2001/XMLSchema#string

P698

24915117

http://www.w3.org/2001/XMLSchema#string

P932

4154084

http://www.w3.org/2001/XMLSchema#string